Harrison covers the Healthcare sector, focusing on stocks such as Vertex ... on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) today and set a price target ...

The company has also secured strategic partnerships with AstraZeneca for drug development and Ansys for engineering ... developed in partnership with Vertex Pharmaceuticals, has received regulatory ...

Both proposals are subject to conditions, including board approval and no significant changes to the business ... of future ...

VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding ...

Amazon's AWS is making strides in the AI race, leveraging open-source models and data advantage to catch up to Microsoft and ...

Slack's survey of over 17,000 desk workers found slowing excitement for AI among employees and a lack of AI training. The nomination of Rubio, a China hawk who's been sanctioned by Beijing, comes ...

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle ...